Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8406367 | 1.00 | MAPT (0.48) | MAPTTSHRTHRBLMNADNM1 | |
| SCHEMBL8406872 | 1.00 | MAPT (0.48) | MAPTTSHRTHRBLMNADNM1 | |
| SCHEMBL9847459 | 1.00 | MAPT (0.48) | MAPTTSHRTHRBLMNADNM1 | |
| SCHEMBL30892701 | 1.00 | MAPT (0.48) | MAPTTSHRTHRBLMNADNM1 | |
| SCHEMBL5985987 | 0.97 | — | — | |
| SCHEMBL13127086 | 0.97 | — | — | |
| SCHEMBL24926247 | 0.88 | MAPT (0.52) | MAPTTSHRTHRBLMNADNM1 | |
| SCHEMBL19853017 | 0.88 | MAPT (0.52) | MAPTTSHRTHRBLMNADNM1 | |
| SCHEMBL10231127 | 0.88 | — | — | |
| SCHEMBL8173118 | 0.88 | MAPT (0.52) | MAPTTSHRTHRBLMNADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006472-B2 | Methods for the synthesis of 13C labeled plasmalogen | PHENOMENOME DISCOVERIES INC. (CA) | 2015-04-14 | — | — | US | disclosed |
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | MED-LIFE DISCOVERIES LP (CA) | 2014-10-30 | — | — | US | disclosed |
| WO-2013071412-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | PHENOMENOME DISCOVERIES INC. (CA) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | PLPBP, SGMS2, PCCA | MAPT 4453/4885TSHR 2733/4885THRB 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.